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Background: Oxidative modification of low density lipoproteins (LDL) convert these native particles into
pathogenic, immunogenic and atherogenic particles. Factors enhance LDL oxidation are poorly understood,
especially in conditions of hyperglycemia. The present study was conducted to investigate which metabolic
conditions are associated with the promotion of LDL oxidation in different glycemic situations.
Methods: Adult male participants (274) were selected from patients admitted to the outpatient department of
Diabetes Center in Al-Noor Specialized Hospital in Makkah and other citizens and residents in the city. The studied
group was classified into three sub-groups: Group-I: control group of non-diabetic normal subjects, Group-II:
subjects with impaired glucose tolerance (IGT) and Group-III: cases of type-2 diabetes mellitus (DM). Measurement
of fasting blood glucose, 2 hour post-prandial blood glucose, glycosylated hemoglobin (HbA1c), triglycerides, serum
cholesterol, HDL-cholesterol, LDL-cholesterol, ox-LDL, Total Antoxidant capacity (TAC) and Malondialdehyde (MDA)
were performed. The obtained results were statistically analyzed.
Results: Oxidation of native LDL increase nearly two folds in Type-2 DM group compared to controls. There is also
significant increase in Ox-LDL of IGT group compared to controls. The correlation between Ox-LDL concentration
and HbA1c in the whole population of the study confirms the increased Ox-LDL in subjects with hyperglycemia.
A negative correlation exists between the concentration of Ox-LDL and total antioxidant capacity (TAC) in each
studied group and in the whole population of the study as well. A positive correlation also exists between Ox-LDL
concentrations and LDL values, more clear in controls and Type-2 DM, while this correlation was not significant in
IGT group. The ratio of LDL oxidation as expressed by ox-LDL/LDL was increased in IGT group compared to control.
More significant increase was observed in type-2 DM group.
Conclusion: We concluded that the concentration of Ox-LDL increased in subjects with type-2 DM and IGT compared
to controls. Moreover, oxidation of native LDL was associated with low levels of TAC and positively correlated with LDL
levels, total cholesterol, HbA1c, body mass index (BMI) and increased age.
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It is now widely accepted that oxidative modification of
low density lipoproteins (LDL) convert these native
particles into pathogenic [1], immunogenic [2,3] and
atherogenic [4,5] particles. Current clinical research ad-
dresses the oxidation of LDL as a causative and initiating
event in many pathological conditions and the oxidative
modification of LDL enhances its atherogenicity [6].
Ox-LDLs are pathogenic particles, they have a number
of biologic activitiesthat contribute to the process of
atherosclerotic lesion formation and other diseases. Re-
moval of Ox-LDL from circulating blood is a promising
therapeutic strategy against atherosclerosis and many
other diseases [7]. This goal cannot be achieved without
a better understanding of the processes by which native
LDL get oxidized.
In spite of the considerable knowledge and literature
that support the correlation between circulating Ox-
LDL and many pathologic conditions, to the best of our
knowledge, there remains a gap regarding the biochem-
ical status of the blood and the biological conditions of
the body that enhance oxidation of native LDL. More
understanding of the role of oxidation of lipoproteins
may allow more rationally targeted diagnostic and thera-
peutic procedures in clinical applications.
The chemical composition of LDL makes these parti-
cles susceptible to oxidation by different lipid oxidants.
The polyunsaturated acyl chains of cholesterol esters,
phospholipids and triglycerides are vulnerable to oxida-
tion, as is the sterol of free cholesterol and cholesterol
esters.
The apolipoprotein B-100, made of 4536 amino acid
residues, with many exposed tyrosines and lysines, which
can be directly oxidized or modified by lipid oxidation
products. The in vivo mechanism of LDLoxidation re-
mains unclear and there are different mechanisms that
may be responsible for the process. They are divided
into enzymatic and non-enzymatic processes. The non-
enzymatic process of modification involves free transi-
tion metal ions such as iron and copper, which are
involved in catalyzing lipid peroxidation. The enzymatic
process involves a number of different enzyme systems,
such as lipoxygenases, myeloperoxidase which catalyses
the formation of hypochlorousacid leading to the forma-
tion of acetylated LDL, NADPH oxidases, and nitric
oxide synthases [8].
Although native LDL are exposed to all enzymatic and
non-enzymatic oxidants, they are protected by a potent
array of antioxidants in plasma. Moreover, some of these
antioxidants are a part of the LDL composition. The LDL
and other biomolecules are protected from free radical at-
tack by the action of antioxidant capacity in the blood.
A healthy aerobic life is characterized by a steady for-
mation of reactive oxygen species (ROS) and reactivenitrogen species (RNS), balanced by a similar rate of
their consumption by an enzymatic and non-enzymatic,
finely monitored, antioxidant system.
Since enzymatic and non-enzymatic antioxidants work
in a network manner to exert their protective effects, no
single antioxidant could represent the overall antioxidant
status in plasma. Therefore, plasma antioxidant status
isthe result of interaction and cooperation of various an-
tioxidants. The concept of total antioxidant capacity
(TAC) was developed considering the synergistic role of
those antioxidants rather than the simple sum of indi-
vidual antioxidant action [9].
Diabetes mellitus (DM) and impaired glucose toler-
ance (IGT) are associated with many complications in-
cluding hypertension, renal failure and coronary artery
diseases. Previous studies have revealed that the excess
of cardiovascular events are observed in patients with
type- 2 diabetes and that adequate control of Low Dens-
ity Lipoprotein cholesterol has been proved to minimize
the risk, however, lowering LDL will not be a complete
solution. This is clear because at any given level of LDL
concentration, there is great variability in the clinical
expression of the disease. The atherogenic potential of
diabetes could be associated with the modified proteins
as the result of glycation and oxidation. The role of Ox-
LDL as a residual lipid risk attracts considerable atten-
tion [10]. The situations of insufficient and/or inefficient
insulin action were reported tocoincide with increased
concentrations of the Ox-LDL [11], however, in which
biochemical situation would these native LDL undergo
oxidation is not well clarified.
The aim of the current study is to investigate the con-
ditions where LDL undergoes oxidation and the possible
role of the parameters of lipid profile (Total Cholesterol,
Triglycerides, HDL and LDL) as well as the TAC, in
increasing circulating Ox-LDL.
Subjects and methods
This study was conducted in Makkah Al-Mukarama
(KSA). The study protocol was approved by the Biomedical
Ethics Committee, Faculty of Medicine, Umm Al-Qura
University, Makkah, KSA. Ethical approval number
43-01071435.
Participants were selected according to inclusion criteria
from patients admitted to the Outpatient department of
Diabetes Center in Al-Noor Specialized Hospital (Makkah,
KSA) and other residents in the city during the period from
May 2012 up to July 2013. Subjects included are adult
males, aged 18-55, live in Makkah and agreed to participate
in the study. 274 volunteers were subjected to the investiga-
tions, they have been informed about the nature of the
study and the expected risk and they have signed the ethical
consent form. They have also filled out the structured
questionnaire. Measurements of weight, height and blood
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Mass Index (BMI) was calculated as weight (Kg) divided by
height squared (m2).
The studied group was classified into three sub-groups
according to the American Diabetes Association (ADA)
recommendations for diagnoses of diabetes and classifi-
cation of glucose tolerance [12].
Group-I: Control group of non-diabetic normal sub-
jects who met the following criteria:
Fasting blood glucose: <6.1 mmol/l (<110 mg/dl.) and
2-hour postprandial: <7.8 mmol/l. (<140 mg/dl.)
Group-II: Subjects with IGT who met the following
criteria:
Fasting blood glucose: <7.0 mmol/l (<126 mg/dl.) and
2-hour postprandial: ≥7.8 mmol/l. (≥140 mg/dl.)
Group-III: cases of type-2 DM and subjects who met
the following criteria:
Fasting blood glucose: ≥7.0 mmol/l (≥126 mg/dl.) and/or
2-hour postprandial: ≥ 11.2 mmol/l. (≥200 mg/dl.)
Not categorized as an Insulin Dependent Diabetes
Mellitus (IDDM).
Participants who were excluded from the study were
those of known history of coronary heart diseases (CHD)
or cardiovascular complications of type-2 DM, known
IDDM, those who are younger than 18 or older than
55 years old and those with familial hypercholesterolemia.
Information regarding exclusion criteria was obtained
from the medical care provider and physicians, patient
records or directly from the participants.
Methods
Blood collection and storage
Blood samples were drawn in ethylene diamine tetra acetic
acid (EDTA)-containing vacationer tubes. For serum sam-
ples, blood was collected in plan tubes and left for 30 min,
then centrifuged for 15 min at 3000 rpm and the serum
samples obtained. The tubes were then properly labeled
and sent directly to the biochemistry laboratory. Serum
samples that were intended for long storage were kept
in -80°C up to the date of analysis.
Measurement of oxidized low density lipoproteins
(Ox-LDL)
Ox-LDL was measured using the commercially available
Mercodia Ox-LDL Competitive ELISA kit (Mercodia
AB, Sylveniusgatan 8A, SE-754 50 Uppsala, Sweden),
intended to be used for the in vitroquantitative determin-
ation of Ox-LDL in human blood plasma. MercodiaOx-
LDL ELISA kits uses Holvoet et. al. monoclonal antibody,
4E6, which is specific for oxidatively modified LDL [13].
The 4E6 antibody is directed against a conformational epi-
tope in the apoB-100 moiety of LDL that is generated as a
consequence of aldehyde substitution of the lysine residues
of apoB-100.The principle of the procedure is based on the fact
that Ox-LDL in the sample competes with a fixed
amount of Ox-LDL bound to the microtiter well for the
binding to the biotin-labeled specific antibodies 4E6.
After a washing step that removes un-reactive sample
components, the biotin-labeled antibody bound to the
well is detected by HRP-conjugated streptavidin. After a
second incubation and an additional washing step, the
bound conjugate is detected by reaction with 3,3’,5,5’-tet-
ramethylbenzidine (TMB). The reaction is stopped by
adding acid to give a colorimetric endpoint that is read
spectrophotometrically.
Measurement of total antioxidant capacity (TAC)
For the assessment of TAC, we used the Cayman
Antioxidant Assay Protocol. The assay can be used to
measure the TACin the plasma, serum, urine, saliva,
and/or cell lysates. Aqueous- and lipid-soluble antioxi-
dants are not separated in this protocol which de-
scribed first by Miller et al. [14], thus, the combined
antioxidant activities of all vitamins, proteins, lipids,
glutathione, uric acid, and others are assessed.
The principle of the assay relies on the ability of
antioxidants in the sample to inhibit the oxidation of
ABTS* (2,2-Azino-di-[3-ethylbenzthiazoline sulphonate]) to
ABTS*+ by metmyoglobin. The amount of ABTS*+ pro-
duced can be monitored by reading the absorbance at
750 nm or 405 nm. Under the reaction conditions used, the
antioxidants in the sample cause suppression of the
absorbance at 750 nm or 405 nm to a degree which is
proportional to their concentration. The capacity of
the antioxidant in the sample to prevent ABTS* oxida-
tion is compared with that of Trolox, a water-soluble
tocopherol analogue, and is quantified as millimolar-
Trolox equivalents.
Measurement of Malondialdehyde (MDA)
MDA was measured using TBARS assay kit (Cayman
Chemical Company, Ann Arbor, MI, USA) for assaying
lipid peroxidation in plasma, serum and urine.
The principle of the assay, based on the procedure of
Dawn-linsley et al. [15], is that the MDA-TBA adduct
formed by the reaction of MDA and thiobarbituric acid
(TBA) under high temperature (90-100°C) is measured
calorimetrically at 530–540 nm. Concentration of MDA
was expressed in (μM MDA).
Measurement of routine chemistry
Measurements of glucose, HbA1c, total cholesterol
(TC), triglycerides (TG), high density lipoprotein (HDL)
and LDL were done using the standard procedures and
available commercial kits in a fully automated system
(COBAS integra 400 plus).
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C plus second generation, HDL-C plus third generation,
reagents (Roche Diagnostics, Indianapolis, IN) were used
on the Chemistry Analyzer to determine levels of TC,
TG, LDL-cholesterol and HDL-cholesterol, respectively.
All assays were done following the recommended proce-
dures for instrument operation, calibration, quality control,
and assay guidelines. The instrument was calibrated using
calibrator for automated systems (Roche Diagnostics) for
glucose, TCand TAG, and calibrator for automated systems
lipids (Roche Diagnostics) for LDL-cholesterol and HDL-
cholesterol.
Results were expressed for all parameters in mg/dl. Ex-
cept for HbA1c, where it was expressed as percentage of
glycosylated hemoglobin [16].
Statistical analysis
Descriptive statistics and one way ANOVA were used to
compare the concentration of Ox-LDL as well as the
other metabolic parameters between the three groups.
Pearson correlation and regression procedures were used
to find correlation between Ox-LDL concentration and
the different studied parameters. P value of < 0.05 was
considered as statistically significant.
Degree of oxidation of LDL alone was analyzed in correl-
ation with the different metabolic parameters and TAC in
the three groups. All statistical methods were performed
using SPSS for windows (version 20, SPSS Inc.).
Results
After exclusion of cases according to our exclusion cri-
teria, 274 successful cases were included in the study,
categorized into three groups according to their fasting
and 2 hours Post Prandial glucose result. Normal con-
trols were 125 subjects, IGT group were 77 subjects and
72 subjects of Type-2 DM.Table 1 Characteristics and glucose tolerance of the studied g
Control IGT
n = 125 n = 77
Age (Years) 34 ± 9 39 ± 10
BMI (kg/m2) 28.3 ± 4.9 31.1 ± 5.1
SBP (mmHg) 124 ± 15 129 ± 12
DBP (mmHg) 82 ± 11 83 ± 8
FBS (mg/dl.) 91 ± 10 116 ± 21
2hrPP BS (mg/dl.) 109 ± 18 167 ± 19
HbA1c% 5.0 ± 0.6 6.7 ± 1.2
HbA1c mmol/mol 31.1 ± 7.1 49.7 ± 12.8
Results are expressed as mean ± SD.
pa: p value when control group was compared to IGT group.
Pb: p value when control group was compared to Type2 DM group.
NS: not significant.
Abbreviations: BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blooThe IGT group showed an increase in the BMI com-
pared to the other two groups.
Markers of hypertension, as expressed in Systolic
Blood Pressure (SBP) and Diastolic Blood Pressure
(DBP), were elevated in Type-2 DM group. The SBP
and DBP in the control group tend to be in normal
range values. Characteristics and glucose tolerance of
the studied groups are summarized in Table 1.
Normal lipid profile as expressed in terms of serum
TC, TG, HDL-cholesterol, LDL-cholesterol and LDL/
HDL ratio were observed in control group as shown in
Table 2.
Oxidative stress parameters as shown in Table 3, dem-
onstrated an increase in lipids peroxidation with de-
creased of TAC in IGT and type-2 DM groups compared
to control group.
Oxidation of native LDL increased nearly two folds in
the type-2 DM group compared to controls. The differ-
ence was significant, p < 0.001.
TAC was found to be low in IGT group compared to
control. More decrease in TAC was found in Type-2 DM
group p < 0.001. The ratio of LDL oxidation as expressed
by Ox-LDL/LDL was increased in IGT and Type-2 DM
groups compared to control as shown in Table 3.Correlations
Table 4 shows the correlations between Ox-LDL con-
centration and selected parameters in all the studied
subjects.
Ox-LDL was found to be increased with age, the
Pearson correlation coefficient (r = 0.42) in all subjects
the correlation was significant (p < 0.001). BMI also
showed a weak, but significant, positive correlation
(r = 0.21) with Ox-LDL concentration in the studied
group, p < 0.01.roups
Type2 DM pa pb
n = 72
42 ± 9 < 0.001 < 0.001
30.2 ± 5.1 < 0.001 < 0.01
136 ± 13 < 0.05 < 0.001
89 ± 11 NS < 0.001
193 ± 65 < 0.001 < 0.001
298 ± 79 < 0.001 < 0.001
8.5 ± 2.1 < 0.001 < 0.001
69.4 ± 22.5 < 0.001 < 0.001
d pressure, FBS Fasting blood sugar, 2hrPP Two hour post-prandial blood sugar.
Table 2 Lipids profile of the studied groups
Control IGT Type2 DM pa pb
n = 125 n = 77 n = 72
CHOL. (mg/dl.) 200 ± 53 240 ± 59 262 ± 79 < 0.001 < 0.001
TG (mg/dl.) 160 ± 78 213 ± 118 248 ± 158 <0.01 < 0.001
HDL-C (mg/dl.) 48.7 ± 16 53.2 ± 17 46.5 ± 16 NS NS
LDL-C (mg/dl.) 118 ± 31 141 ± 38 153 ± 49 < 0.001 < 0.001
LDL-C/HDL-C 2.60 ± 0.9 2.92 ± 1.3 3.53 ± 1.4 NS < 0.001
Results are expressed as mean ± SD.
pa: p value when control group was compared to IGT group.
Pb: p value when control group was compared to Type2 DM group.
NS: not significant.
Abbreviations: CHOL Cholesterol, TG Triglycerides, HDL-C High density
lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol.
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HbA1c in the whole population of the study confirms
the increased Ox-LDL concentration in subjects with
hyperglycemia. The Pearson correlation coefficient
(r =0.60), as shown in Table 4, was found to be significant
(p < 0.001). This correlation was shown in Figure 1.
A positive correlation also exists, as shown in Table 4,
between Ox-LDL concentrations and LDL values, more
clear in controls, (r = 0.24) and type-2 DM (r =0.12),
while this correlation is not significant in IGT group.
In all subjects, Pearson correlation coefficient (r =
0.36) was found to be significant with (p < 0.001). as
shown in Figure 2.
MDA levels were positively correlated with Ox-LDL
levels in the study, Pearson correlation coefficient (r =0.44)
was found to be significant as shown in Table 4.
A negative correlation exists between the concentra-
tion of Ox-LDL and the concentration of TACin each
group as well as in the whole population of the study.
The correlation between the concentrations of Ox-LDL
and TAC in the studied groupswas shown in Figure 3.Table 3 Oxidative stress parameters of the studied groups
Control IGT
n = 125 n = 77
Ox-LDL 73.5 ± 27.5 108.7 ± 23.7
(U/L)
MDA 4.46 ± 1.98 5.77 ± 2.50
(μM)
TAC 1.384 ± 0.688 1.000 ± 0.397
(mM)
Ox-LDL /LDL-C 25.12 ± 11 31.81 ± 11
Results are expressed as mean ± SD.
pa: p value when control group was compared to IGT group.
Pb: p value when control group was compared to Type2 DM group.
Abbreviations: Ox-LDL Oxidized low density lipoprotein, MDA Malondialdehyde, TACDiscussion
Ox-LDL in diseases
Ox-LDL is attracting considerable importance in recent
biomedical research. Oxidation of LDL and their subse-
quent uptake by macrophages inside the arterial wall are
considered crucial steps in the process of atherosclerosis.
Indeed, macrophages do not take up native LDL parti-
cles, which can be recognized by LDL receptor, unless
they undergo in vivo modifications such as oxidation,
where they are no longer been recognized in their nor-
mal metabolic pathway [1]. The process is considered as
an initiating event of cardiovascular disease (CVD).
According to many clinical studies, there is enough
evidence that lowering LDL levels is an important pre-
vention strategy for diabeticcardiovascular complications
[17]. However, a residual risk of CVD tends to persist,
this is suggested by many studies, at least partly, due to
increased Ox-LDL levels [17,18]. Moreover, targeting
Ox-LDL was found to improve insulin sensitivity and
immune cell function thereby reducing vascular inflam-
mation in diabetic conditions in animal models [19].
Understanding the mechanisms and conditions that en-
hance LDL oxidation is of vital importance.
Oxidative stress parameters and Ox-LDL
Oxidative stress is the imbalance between oxidants and
antioxidants in the body caused by free radicals. Free
radicals can be defined as reactive chemical species,
mainly ROS and RNS, having a single unpaired electron
in an outer orbit [20]. Oxidative stress is balanced by the
body’s endogenous antioxidant systems and the ingestion
of exogenous antioxidants.
The antioxidant defense system in the human body is
a powerful system working in synergistic manner to pro-
vide what is known as TAC.
In the present study, there was an increase in lipid
peroxidation with decreased TAC in IGT and type-2 DMType2 DM pa pb
n = 72
143.5 ± 21.9 < 0.001 < 0.001
7.91 ± 3.17 < 0.001 < 0.001
0.817 ± 0.248 < 0.001 < 0.001
42.40 ± 25 < 0.01 < 0.001
Total antioxidant capacity.
Table 4 Correlations between ox-LDL and selected
parameters in the whole population of the study













*: significant at 0.01 level.
**: significant at 0.001 level.
Figure 2 Correlation between Ox-LDL and LDL in all
studied groups.
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LDL in the present study increased by nearly two folds
in type-2 DM group compared to control subjects.
There is also significant increase in the mean Ox-LDL of
group-II (IGT), compared to controls (P < 0.001). This
increase can be read as a logical result of decreased anti-
oxidant capacity observed in type-2DM and IGT groups.
TAC was significantly decreased (P < 0.001) in IGT
group compared to control, more significant decrease
(P < 0.001) was observed in type-2 DM group.
A negative correlation exists between the concentra-
tion of Ox-LDL and mM concentration of TAC in each
studied group and in the whole population of the study
as well. Pearson correlation coefficient was found to be
(r = -0.59) as shown in Figure 3b, (r = -0.56) Figure 3c
and (r = -0.23) Figure 3d, in controls, IGT and type-2
DM groups, respectively, while (r = -0.51) as shown inFigure 1 Correlation between Ox-LDL and HbA1c in all
studied groups.Figure 3a, in all the studied population (P < 0.001). De-
creased TAC seems to play a vital role in the oxidation
of LDL, this may explain the persistence of CVD risk
even in case of controlled lipid and normal LDL concen-
tration. We think that native LDL may undergo oxida-
tion even when there is normal lipid profile and normal
LDL concentration if there is low antioxidant defense in
the body. The effect of high levels of LDL on the process
cannot be neglected, however, the antioxidant status of
the blood has the stronger effect according to our data.
Kopprasch et al. [21] suggest that Ox-LDL levels were
not associated with the parameters of the oxidative/anti-
oxidative balance in the blood. They reported that LDL
cholesterol and triglycerides were the strongest predic-
tors of circulating Ox-LDL levels, followed by HDL-
cholesterol. They added that the strong correlation of
Ox-LDL with LDL-cholesterol and TAG indicates that
LDL oxidation in IGT is preferentially associated with
dyslipidemia and that Ox-LDL increase may explain the
high atherogenic potency of dyslipidemia in the pre-
diabetic state [21].
Our study agrees with this positive correlation be-
tween Ox-LDL and dyslipidemia, however, it is not
strong enough to exclude the effect of oxidative stress as
suggested by Kopprasch et al. [21]. Furthermore, TAC
has the major role in the oxidation of LDL with higher
correlation coefficient than lipid profile parameters as
suggested by our results.
The effect of antioxidant status on LDL oxidation was
further studied for the possible effects of dietary supple-
mentations with sources of antioxidant vitamins and
polyphenols on antioxidant capacity and oxidation of
LDL [22]. A decrease in Ox-LDL was reported after
consumption of grape juice, a source of polyphenols
[23], green tea [24], cocoa drink and cranberries
[25,26]. Vitamin E and C were studied as well as carot-
enoids in long-term supplementation and they were
Figure 3 Correlation between Ox-LDL and total antioxidant capacity. a: in all studied groups. b: in control group. c: in IGT group. d: in
type-2 DM group.
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lipid peroxidation [27,28].
Lipid peroxidation as expressed in terms of MDA con-
centration was found to be significantly elevated (P < 0.001)
in type-2 DM and IGT groups compared to control group.
Matsuda et al. [17] found that MDA-LDL level was sig-
nificantly correlated with the levels of LDL-cholesterol, TG,
HDL-cholesterol, but not with age, BMI, waist circumfer-
ence, blood pressure, creatinine or HbA1c levels. Thus, they
suggest that in addition to statin therapy, the management
of dyslipidemic MS components is important for reducing
the oxidization of LDL and, ultimately, the risk of cardio-
vascular events in high-risk DM patients [17].
Ox-LDL and glycemic status
Diabetes is a group of metabolic diseases characterized
by hyperglycemia resulting from defects in insulin secre-
tion, insulin action, or both [29]. In Saudi Arabia, the
overall prevalence of DM in adults is 23.7% [30]. The
prevalence of diabetes is increasing, as a consequence of
increasing incidence due to demographic changes such
as aging, and as a result of risk factors such as obesityand sedentary life becoming more common [31]. In
2011 a study was conducted in KSA and revealed that
the prevalence of DM type-2 in Saudi Arabia has in-
creased by a whopping 10.0% in just a decade [32]. This
may give a strong justification for studies, such as the
present study, dealing with the etiology and mechanism
of complications associated with diabetes and other situ-
ations of hyperglycemia.
The present study investigates parameters of dyslipid-
emia and oxidative stress in correlation to Ox-LDL in
three groups of different glycemic situations.
In the present study, Ox-LDL levelsare higher in IGT
and type-2DM subjects when compared to control p <
0.001. Higher levels of Ox-LDL were observed in dia-
betics suggesting that oxidation of LDL is positively in-
fluenced by hyperglycemia. In contrast, Schwenke, et al.
[33] found that glycemic status negatively influenced
LDL oxidizability, with a paradoxical reduction in LDL
oxidizability, as indicated by a lower LDL oxidation rate
with increased extent and duration of glucose intoler-
ance. They added that the difference was only slightly
attenuated by adjustment for relevant demographic,
Figure 4 Correlation between Ox-LDL and BMI in all
studied groups.
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tentially influence LDL oxidation [33].
Previous studies suggest that serum levels of Ox-LDL
were significantly increased in IGT versus NGT subjects
[21]. Our results show increased oxidation of native LDL
in cases of IGT.Ox-LDL is positively correlated with FBS
levels in the studied group, (r = 0.56) and (P < 0.001). A
stronger positive correlation observed between Ox-LDL
and the 2hPP values was also significant, (r = 0.62) and
(P < 0.001). These findings suggest that oxidizability of
native LDL is higher in hyperglycemia. The positive
correlation between Ox-LDL concentration and HbA1c
in the whole population of our study confirms the in-
creased Ox-LDL concentration in subjects with hyper-
glycemia. The Pearson correlation coefficient (r = 0.60)
was found to be statistically significant P < 0.001.Effect of age and BMI on the oxidation of LDL
Those who were 55 or older were excluded from the study
because of the known increased oxidative stress in elderly
people [34,35], which may give misleading results.
The diabetic and IGT groups were older in age in
comparison with the normal healthy group, as shown in
Table 1, aconstant observation in previous studies as
stated by Li, Saito et al. [36], old age is a non-modifiable
risk factor for CVD and other diseases related to aging,
IGT and type-2 diabetes are correlated with older ages.
In the present study,Ox-LDL was found to be increased
with age, the Pearson correlation coefficient (r = 0.422) be-
tween age and Ox-LDL in the whole subjects was found to
be significantP < 0.001. This may be as a result of decreased
antioxidant capacity observed in older people in previous
studies and in the present study as well.
The BMI was significantly increased in type-2 DM
group (P < 0.05) and more significantly increased in the
IGT group (P < 0.001).So many studies consider obesity as a strong risk fac-
tor of type-2 diabetes, its cardiovascular complications
and independent risk factor of CVD [37]. Our results in
the present study show a significant positive correlation
between BMI and Ox-LDL concentration (p < 0.01). This
may explain the increased prevalence of type-2 DM and
cardiovascular complication observed in obese subjects
by many previous studies [38]. The strong link between
Ox-LDL and risk of CVD was well established, and even
their vital role in foam cell formation. Our results indi-
cate higher concentrations of Ox-LDL in obese cases.
Ox-LDL and lipid profile
Dyslipidemia is strongly linked to insulin resistance and
other features of the metabolic syndrome. Diabetic dys-
lipidemia is a well-recognized risk factor for atheroscler-
otic CVD, and lipid lowering drugs proved an effective
treatment for decades [39]. Ox-LDL concentration was
found to be positively correlated with TC levels in the
studied group (r = 0.32) and (P < 0.001). A weak positive
correlation was also observed with TG levels. Diwadkar
et al. [40] suggest that elevated levels of serum TG may
contribute to the rapid oxidation of LDL seen in diabetic
subjects [40].
A positive correlation also exists between Ox-LDL
concentrations and LDL values, more clear in controls
(r = 0.24) and type-2 DM (r = 0.12), while this correlation
is not significant in IGT group. In all subjects, Pearson
correlation coefficient (r = 0.36) was found to be signifi-
cant with P < 0.001. Our data suggest that oxidation of
LDL increase in case of dyslipidemia and the oxidation
of these particles particularly associated with high levels
of native LDL. This may be handled as a logical conclu-
sion in that, if there is more native LDL then there
should be more Ox-LDL. However, we think that it is a
whole situation of dyslipidemia that enhances LDL oxi-
dation. Sedentary lifestyle and obesityprovide a good
chance for disturbance in lipid profile and consequently
oxidation of LDL and related cascade of events. Ox-LDL
concentration in the present study was found to be posi-
tively correlated with BMI as shown in Figure 4.
Our findings are also supported by the results reported
by Magge, et al. [41] who concluded that obese pre-diabetic
adolescents have a significantly more atherogenic lipopro-
tein profile compared with obese normglycemic peers [41].
Another study reported that the diabetic patients with poor
glycemic control exhibited a significant increase in choles-
terol and TG and decrease in HDL levels [42]. Therefore,
the present study suggest that management of obesity and
dyslipidemia, which are more common among Saudi
office workers than general population according to
previous studies [43], may help in prevention of LDL
oxidation and manage further complications caused by
the increased Ox-LDL.
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The ratio of LDL oxidation as expressed by Ox-LDL/
LDL was increased in IGT group compared to the nor-
mal control (P < 0.01). More significant increase was ob-
served in type-2 DM group (P < 0.001). Thus, our data
suggest that not only does the concentration of Ox-LDL
increase, but also LDL oxidizability increases in diabetic
subjects and in cases of IGT.
Conclusion
In conclusion, our study has found that Ox-LDL levels
increase in IGT and type-2 DM subjects when compared
to control.
Oxidation of LDL is negatively correlated with the
TAC of blood. A positive correlation between Ox-LDL
and concentration of native LDL was also found, how-
ever, low antioxidant capacity play the major role in LDL
oxidation.
More studies are recommended to investigate whether
increasing the antioxidant capacity either by dietary or
medical intervention routes will prevent or reduce oxi-
dation of LDL.
This study also shows a positive correlation between
BMI and elevated levels of Ox-LDL. Weight control is
recommended to avoid the increase in atherogenicOx-
LDL particles.
Limitations of the study
The study included only Saudi male participants, other
studies including women and different ethnic groups are
needed to confirm these findings.
The study measure antioxidants as a total sum. Measur-
ing dietary and enzymatic antioxidants in similar studies
may be beneficial.
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